Arkolith/Insider Trading/TOVX/Form 4

Shallcross Steven A

CEO and CFO, DirectorTheriva Biologics, Inc. (TOVX) · full profile →Form 4 · filed Jan 26, 2023
Net Buying
Open-Market Buys
$22K
Open-Market Sells
$0
Net Open-Market Flow
$22K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 25, 2023Buy(P)25K$0.87$22K160K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-23-006677) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML